Advanced Transdermal Solutions
SENDS™ Technology: Advanced Delivery Science for Transdermal Therapeutics.
The patented SENDS™ platform is a self-emulsifying delivery technology designed to improve the dispersion and transport of selected active ingredients across the skin. By supporting room-temperature formulation, scalable manufacturing, and transdermal delivery, SENDS™ provides 11Three with a flexible technology foundation for developing next-generation therapeutic assets.
From formulation science to commercial execution, SENDS™ is the enabling platform behind 11Three’s transdermal development strategy.
Supporting efficient transdermal delivery.
Self-Emulsifying Platform
SENDS™ creates a uniform delivery matrix through spontaneous self-assembly, eliminating the need for high-shear processing.
Transdermal Application
Our technology supports the efficient transport of therapeutic compounds through the skin, enhancing delivery efficacy.
Room-Temperature Processing
SENDS™ allows for conventional blending, enabling scalable and cost-effective manufacturing processes.
Scalable Manufacturing
Designed for seamless integration into existing production lines, supporting rapid commercialization.
Scientific Validation
SENDS™ has been evaluated through prior work involving DuPont and the University of Maryland
University of Maryland Collaboration
Our partnership with the University of Maryland has been pivotal in applied pharmaceutics and formulation evaluation.
DuPont Testing
DuPont’s Franz Diffusion Cell testing has validated SENDS™’s transdermal delivery performance, reinforcing our scientific foundation.
Step 1
API Selection
Identify and select the most suitable active pharmaceutical ingredients for transdermal delivery.
Step 2
SENDS™ Formulation
Develop a self-emulsifying formulation using SENDS™ technology to optimize skin penetration.
Step 3
Remy cGMP Manufacturing
Utilize cGMP-certified facilities to ensure high-quality, scalable production of transdermal systems.
Step 4
Univec eDRLS / NDC
Integrate FDA labeler and NDC infrastructure for regulatory compliance and market readiness.
Revolutionizing Drug Delivery
The Future of Transdermal Therapeutics
11Three is advancing next-generation transdermal drug delivery systems using licensed SENDS™ technology. Our focus on scientific development, strategic partnerships, and scalable commercialization supports the development of innovative transdermal therapeutic solutions. With an emphasis on quality, compliance, and efficient execution, 11Three is positioned to expand the possibilities for patient care and pharmaceutical development.